Related Experiment Videos
[A study of antithrombin systems during heparin therapy]
La Nouvelle Presse Medicale
|October 16, 1982
Summary
Heparin therapy for venous thromboembolism significantly decreases antithrombin III (AT-III) levels, correlating with heparin concentration. Other thrombin inhibitors like alpha 2M and alpha 1 AT showed no significant changes.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Context:
- Venous thromboembolic disease (VTE) is a significant clinical concern.
- Heparin is a primary anticoagulant therapy for VTE.
- Understanding the impact of heparin on endogenous anticoagulants is crucial for optimizing VTE treatment.
Purpose:
- To investigate the effects of heparin therapy on plasma levels of key thrombin inhibitors.
- To correlate changes in antithrombin III (AT-III) with heparin plasma levels during VTE treatment.
- To assess the impact on alpha 2 macroglobulin (alpha 2M) and alpha 1 antitrypsin (alpha 1 AT) levels.
Summary:
- Plasma levels of antithrombin III (AT-III), alpha 2 macroglobulin (alpha 2M), and alpha 1 antitrypsin (alpha 1 AT) were measured in 19 VTE patients before and during heparin therapy.
- A significant decrease in AT-III levels was observed during heparin treatment, correlating with heparin plasma levels.
- No significant changes were found in alpha 2M and alpha 1 AT levels, and total plasma antithrombin activity remained stable. However, a notable increase in alpha 2M was observed in patients with AT-III levels below 60%.
Impact:
- This study highlights the consumption of AT-III during heparin therapy for VTE.
- Findings suggest that monitoring AT-III levels may be important in specific patient subgroups undergoing heparin treatment.
- The observed changes in thrombin inhibitors provide insights into the complex anticoagulant mechanisms and potential therapeutic challenges in VTE management.